HCW Biologics Inc. (HCWB)

1.1600 -0.1200 (-9.38%) At close: 04:00PM EDT

HCW Biologics Inc.

2929 North Commerce Parkway
Miramar, FL 33025
United States
954 842 2024
https://www.hcwbiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Hing C. Wong Ph.D.	Founder, CEO, Director & Secretary	425.88k	N/A	1954
Ms. Rebecca Byam CPA, M.B.A.	Chief Financial Officer	300.3k	N/A	1956
Dr. Peter Rhode Ph.D.	Chief Scientific Officer & VP of Clinical Operations	251.16k	N/A	1958
Ms. Nicole Valdivieso Esq.	Vice President of Legal Affairs	N/A	N/A	N/A
Ms. Raquel Diaz M.S.	Director of Human Resources	N/A	N/A	N/A
Mr. Lee D. Flowers	Senior Vice President of Business Development	N/A	N/A	1946

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Corporate governance

HCW Biologics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.